Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
Healthcare
$0.69 -3.42%
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
52W Low $0.89High $2.09
Volume 0.17M
Average 0.13M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$10.54M
FY 2025 · Annual
Net Income
-$10.41M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 126.49K | 833.21K | 1.57M | 2.24M | 2.44M |
| Selling, General & Admin | 11.64K | 20.94K | 600.19K | 9.64M | 8.1M |
| Operating Expenses | 138.13K | 854.15K | 3.94M | 12.24M | 10.54M |
| Depreciation & Amortization | 138.13K | 854.15K | 0 | 12.24M | 0 |
| EBITDA | 0 | 0 | (11.43M) | 48K | (10.41M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (138.13K) | (854.15K) | (3.94M) | (12.24M) | (10.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 48K | 125.64K |
| Interest Expense | 0 | 0 | 1.64M | (4.34M) | 0 |
| Other Income / Expenses | 0 | 0 | (9.13M) | (4.29M) | 125.64K |
| Income Before Tax | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | (0.03) | (0.44) | (0.56) | (0.33) |
| EPS (Diluted) | (0.00) | (0.03) | (0.44) | (0.56) | (0.33) |
| 29.61M | 29.61M | 29.61M | 29.54M | 31.65M | |
| 29.61M | 29.61M | 29.61M | 29.54M | 31.65M |
TELO Earnings Waterfall · TTM
NASDAQ:TELO · Revenue to Net Income
Key Ratios
EPS$-0.29
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-7.1
P/S Ratio0.0
Analysis
$0 of revenue converted into -$9.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.29, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3 | S-3 filing | Oct 27, 2026 | |
| 8-K | Current report | Oct 6, 2026 | |
| 8-K | Current report | Sep 17, 2026 | |
| 8-K | Current report | Sep 16, 2026 | |
| 8-K | Current report | Sep 14, 2026 |
How much revenue does TELO generate?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported $0.00 of revenue in fiscal 2025.
Is TELO profitable?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported -$10.41M of net income.
Continue the stock analysis
Jump to another research area for this company.